Brazil: Brazil Focus - Growth For The Biotech Sector

The Brazilian government is investing in the development of biopharmaceuticals through partnerships with innovative multinationals, local pharma companies and public research and development institutions, as Gabriela Salerno and Rana Gosain of Daniel Advogados report.

In 2001, the worldwide revenue of the pharmaceutical market was around $390 billion. Ten years later, this number increased to almost $1 trillion, with biopharmaceuticals accounting for approximately 15.7%. Forecasts show that this percentage is expected to exceed 20% by 2016. The key regions for the global biologics market are the US, Europe, Japan and Brazil, Russia, India and China, which together accounted for 83% of this market in 2014.

Based on these statistics, the research, development and innovation process of the pharma industry has been gradually changing due to the so-called modern biotechnology revolution, which represents a whole new world of possibilities for the treatment of autoimmune diseases, cancer and others.

However, several important differences between synthetic drugs and biopharmaceuticals must be taken into consideration. The former are usually small stable molecules which can be easily manipulated and obtained by a controlled process. On the other hand, biological drugs are quite complex and unstable molecules which can have their structures completely changed when subjected to minor variations.

Because of their complexity, identical copies of biopharmaceuticals are extremely difficult to produce and the processes for producing them play a critical role in maintaining their safety and efficacy. Large-scale biotech manufacturing facilities are at least five times more expensive to build compared with synthetic molecule facilities and are also more costly to run.

Therefore, biological drugs are often included in the expression 'the process is the product', indicating the significance of the manufacturing process to guarantee quality. Another parameter that is pivotal for biologics is immunogenicity, which is the ability of a substance to trigger an immune response. Since these substances are generally macromolecules, they are usually immunogenic and therefore they can provoke an immune response which can lead to serious consequences if not properly controlled, such as an immune tolerance breakdown—whereby the body cannot tolerate its own proteins.

In Brazil, the sixth largest pharma market in the world, retail sales jumped from R$28.7 billion ($8.3 billion) in 2010 to R$41.8 billion in 2014, representing an increase of 45.6% over that period. However, in the past few years, the market has undergone some changes. Innovative drugs, which accounted for 44% of sales in value terms in 2010, declined to 39% in 2014, while generics and follow-on biologics (also known as biosimilars) have gained market share, climbing from 55% in 2010 to 61% in 2014.

Although generic drugs are still of great importance to the Brazilian market, recent studies show the need for innovation in the pharma industry. Due to the exponential growth of biotech in the world, the production of biopharmaceuticals seems to have great potential to drive the Brazilian pharma industry.

One main reason for traditional pharma companies to invest in biotech processes for producing new drugs is the expiration of patents covering their blockbuster synthetic drugs in the past few years (the 'patent cliff'). Since Brazil is among the five most important markets for the majority of these companies, it is essential to carefully analyse the current patent scenario in this country.

Cause for optimism

Despite the Brazilian Patent and Trademark Office (INPI) having taken steps to increase the number of patent examiners, the backlog situation has not improved for the simple reason that during the last decade there has been a constant increase in patent filings in Brazil. However, some relevant developments are contributing to the creation a more optimistic scenario, such as the letter of intentions signed by the Brazilian and US governments whereby the INPI would adopt a Patent Prosecution Highway pilot programme to streamline the examination of patent applications, thereby reducing the huge backlog.

Although the pilot programme would apply only to the oil and gas industry, it would be a big step towards efficiency and it could certainly be extended to all technological fields. Also, the INPI published new examination guidelines for patent applications in the biotech field early this year, addressing issues that were not cited in the previous guidelines of 2002 and providing a more uniform and predictable analysis of these applications.

One important player in the examination of patent applications in the biotech/pharma fields in Brazil is the National Health Surveillance Agency (ANVISA), which introduced a significant change in patent prosecution with the publication of Resolution No. 21/2013. The resolution clearly states that besides analysing public health issues, ANVISA has the right to carry out a substantive examination before the INPI if the application refers to any of the active compounds that are said to be of interest to the Brazilian healthcare system.

Some biologicals are included in this list of compounds, such as monoclonal antibodies, enzymes, hormones, proteins, vaccines and haemoderivatives. In theory, if prior approval of an application is denied by ANVISA, it will be sent back to the INPI, which can shelve the application. So far, no patent application for which prior approval has been denied has been shelved by the INPI.

It is also possible to challenge ANVISA's intervention before the courts by alleging a lack of legal standing to perform a substantive examination. As a result, some courts have issued preliminary injunctions ordering ANVISA to grant prior approval of patent applications on the grounds that ANVISA did not have the competence to conduct a patentability examination.

On the other hand, an unexpected decision from the federal court in Rio de Janeiro in June denied a preliminary injunction and ruled that ANVISA is competent to examine pharma patent applications in terms of patentability requirements. In all likelihood this decision will be used by ANVISA to assert its legitimacy to examine pharma patent applications and Brazilian attorneys will have to be creative to overrule this decision.

In an attempt to keep up with the new biotech wave, the Brazilian government is investing in the development of biopharmaceuticals through partnerships with innovative multinationals, local pharma companies and public research and development institutions. The so-called product development partnerships (PDPs) are guided by the Brazilian Ministry of Health's Ordinance No. 2,531 of November, 2014, which establishes the mandatory requirements for submitting a PDP project.

One of the main objectives of a PDP is to transfer the technology involved in the manufacture of biological products to a Brazilian public R&D institution in order to improve local production and reduce government dependence on imported products.

The rules for approving biosimilars in Brazil are very similar to those adopted by countries considered as leaders in the field. Moreover, in order to be harmonised with international standards, ANVISA is currently issuing guidelines for specific product classes such as heparins and alphainterferon.

It is certain that the Brazilian federal government is keen on improving the country's drug development and medical research capacity so as to stimulate domestic industrial growth. It is therefore no surprise that the government is the primary sponsor of biotech sector growth. In addition, it intends to allocate more resources to spur innovation in local companies producing biological products, particularly for drugs treating cancer and rheumatoid arthritis.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
DANIEL Legal & IP Strategy
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
DANIEL Legal & IP Strategy
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions